Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer

Differences in genetic molecular features including mutation, copy number alterations and DNA methylation, can explain interindividual variability in response to anti-cancer drugs in cancer patients. However, identifying genetic alteration-driven genes and characterizing their functional mechanisms in different cancer types are still major challenges for cancer studies. Here, we systematically identified functional regulations between genetic alteration-driven genes and drug target genes and their potential prognostic roles in breast cancer. We identified two mutation and copy number-driven gene pairs ( PARP1-ACSL1 and PARP1-SRD5A3 ), three DNA methylation-driven gene pairs ( PRLR-CDKN1C , PRLR - PODXL2 and PRLR - SRD5A3 ), six gene pairs between mutation-driven genes and drug target genes ( SLC19A1 - SLC47A2 , SLC19A1 - SRD5A3 , AKR1C3 - SLC19A1 , ABCB1 - SRD5A3 , NR3C2 - SRD5A3 and AKR1C3 - SRD5A3 ), and four copy number-driven gene pairs ( ADIPOR2 - SRD5A3 , CASP12-SRD5A3 , SLC39A11 - SRD5A3 and GALNT2 - SRD5A3 ) that all served as prognostic biomarkers of breast cancer. In particular, RARP1 was found to be upregulated by simultaneous copy number amplification and gene mutation. Copy number deletion and downregulated expression of ACSL1 and upregulation of SRD5A3 both were observed in breast cancers. Moreover, copy number deletion of ACSL1 was associated with increased resistance to PARP inhibitors. PARP1 - ACSL1 pair significantly correlated with poor overall survival in breast cancer owing to the suppression of the MAPK, mTOR and NF-kB signaling pathways, which induces apoptosis, autophagy and prevents inflammatory processes. Loss of SRD5A3 expression was also associated with increased sensitivity to PARP inhibitors. The PARP1 - SRD5A3 pair significantly correlated with poor overall survival in breast cancer through regulating androgen receptors to induce cell proliferation. These results demonstrate that genetic alteration-driven gene pairs might serve as potential biomarkers for the prognosis of breast cancer and facilitate the identification of combination therapeutic targets for breast cancers.